Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
UC expert comments on study to NBC News
The University of Cincinnati's Alberto Espay, MD, commented to NBC News on new research published Oct. 24 that found semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes.
The new study compared semaglutide to seven other diabetes drugs, including metformin, insulin and older GLP-1 drugs, including liraglutide.
Researchers found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The results were consistent across gender, age and weight.
Espay, who was not involved in the study, told NBC News more research is needed to determine if the drugs actually work against Alzheimer's. He noted previous early research showed similar positive effects for people who took drugs including statins or insulin, but none of those potential treatments panned out.
“Just as with statins, NSAIDs and insulin, we should be cautious about claiming semaglutide can treat or prevent Alzheimer’s based on this study alone,” Espay said.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Children exposed to gambling mechanics before they understand money
February 4, 2026
Gambling-style mechanics are becoming a routine part of children’s digital lives, appearing in online games, mobile apps and even sports betting advertisements that surround popular media. University of Cincinnati experts warned in a recent WKRC-TV Local 12 report that long before children understand the value of money, they are learning the emotional highs and lows associated with risk. Online games, such as Roblox and Fortnite, offer fast-paced rewards that can keep children glued to screens.
Study: Synthetic protein potentially improves outcomes for certain subgroups following intracerebral hemorrhage
February 4, 2026
The University of Cincinnati’s Joseph Broderick, MD, presented results from the FASTEST trial at the International Stroke Conference, simultaneously published in The Lancet, that found administering a synthetic protein, recombinant Factor VIIa, can reduce bleeding and potentially improve outcomes for certain patients at the highest risk of continued bleeding following an intracerebral hemorrhage.
UC expert explains 25th Amendment
February 4, 2026
WVXU's Cincinnati Edition talks to a University of Cincinnati political science professor about the 25th Amendment to the U.S. Constitution.